Audentes Therapeutics Inc

Audentes Therapeutics — Technical Presentation (May 2019)

29 slides from Audentes Therapeutics's technical presentation, May 1, 2019

  1. Slide 1: ASPIRO Phase 1/2 Gene Therapy Trial in XLMTM: Update on Preliminary Safety and Efficacy Findings

    ASPIRO Phase 1/2 Gene Therapy Trial in X-Linked Myotubular Myopathy (XLMTM): Update on Preliminary Safety and Efficacy Findings Perry Shieh, MD PhD Associate Professor of Neurology, University of California Los Angeles Exhibit 99.2

  2. Slide 2: Disclosures

    Disclosures Principal Investigator in the INCEPTUS and ASPIRO XLMTM clinical trials Advisory boards Audentes, Sarepta, Roche, Avexis, Biogen Speakers’ bureau Biogen, Alexion, CSL Behring, Grifols

  3. Slide 3: MTM1 gene produces myotubularin protein; X-Linked Myotubular Myopathy

    MTM1 gene produces myotubularin protein1 Myotubularin dephosphorylates critical second messenger proteins 1 2 3 Myotubularin required for correct Muscle growth and differentiation2,3 Cellular organization and structure2–4 Cellular function2,4,5 SR SR, sarcoplasmic reticulum Raess MA, et al. Adv Biol

  4. Slide 4: XLMTM – Natural History

    Annoussamy M, et al. Neurology 2019;92:e1852–67 Beggs AH, et al. Muscle Nerve 2018;57:550–60 Vandersmissen I, et al. Neuromuscul Disord 2018;28:766–7 Amburgey K, et al. Neurology 2017;89:1355–64 XLMTM – Natural History Incidence ≈1 in 40–50K newborn males1–4 Estimated 50% mortality by 18 months2 10-

  5. Slide 5: AT132: rAAV8-Des-hMTM1

    ITR, inverted terminal repeat; Des, human desmin promoter polyA, polyadenylation signal; SA, splice acceptor; SD, splice donor 1. Mack DL, et al. Mol Ther 2017;25:839–54 AT132: rAAV8-Des-hMTM1 First systemic gene therapy utilizing the muscle-specific desmin promoter AAV8 effectively transduces skele

  6. Slide 6: ASPIRO Phase 1/2 Clinical Study of AT132

    CHOP INTEND, Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders BL, baseline; mo, months; Wk, week ASPIRO, NCT03199469; INCEPTUS, NCT02704273 ASPIRO Phase 1/2 Clinical Study of AT132 An open-label, ascending-dose, safety and preliminary efficacy study AT132 administration Inc

  7. Slide 7: ASPIRO Patient Enrollment and Follow-up

    ASPIRO Patient Enrollment and Follow-up Eleven patients enrolled in the INCEPTUS observational run-in study have transitioned into ASPIRO Interim data as of April 8, 2019 Duration in the study (years) Age at dosinga (years) Cohort 1 Cohort 2 Patient ID 0.8 4.1 2.5 4 0.8 0.7 0.7 1.3 6.8 2.3 2.4 Follo

  8. Slide 8: Safety and Tolerability

    Safety and Tolerability

  9. Slide 9: AT132 Well Tolerated with Manageable Safety Profile

    Since the initiation of the study (Sep 2017): there are 47 AEs (including SAEs) considered related/possibly related. There are 35 non-serious AEs related/possibly related Interim data as of April 8, 2019 Cohort 1: 1x1014vg/kg; Cohort 2: 3x1014vg/kg; AE, adverse event; CK, creatine kinase AT132 Well

  10. Slide 10: Muscle Biopsy

    Muscle Biopsy

  11. Slide 11: Robust Transduction, Transcription and Protein Expression

    Cohort 1: 1x1014vg/kg; Cohort 2: 3x1014vg/kg Interim data as April 8, 2019 Robust Transduction, Transcription and Protein Expression AT132 produced dose-dependent increases in the gastrocnemius muscle at Week 24 Patient 1 Patient 2 Patient 3 Patient 5 Patient 6 Patient 7 Patient 8 Patient 9 Patient

  12. Slide 12: Molecular Findings Consistent Across Muscle Groups

    Patient 1 Patient 2 Patient 3 Patient 5 Patient 6 Patient 7 MTM1 mRNA ratio (Transgene:Reference gene) Interim data as April 8, 2019 Molecular Findings Consistent Across Muscle Groups Cohort 1 showed robust increases in transduction, transcription, and protein expression in the vastus lateralis musc

  13. Slide 13: Improvement in Histopathological Hallmarks of XLMTM Cohort 1

    H&E NADH Healthy 5-year-old Baseline Week 24 Week 48 Improvement in Histopathological Hallmarks of XLMTM Cohort 1 Representative Histology Baseline – Classic XLMTM pathology including fiber smallness, internally placed nuclei, and central aggregates of organelles on NADH stain Week 24 – Organelle mi

  14. Slide 14: Histopathological Findings in Cohort 2 Suggest More Rapid Rate of Pathological Recovery

    Healthy 2-year-old Baseline Week 24 Histopathological Findings in Cohort 2 Suggest More Rapid Rate of Pathological Recovery Cohort 1: 1x1014vg/kg; Cohort 2: 3x1014vg/kg H&E, hematoxylin and eosin; NADH, nicotinamide adenine dinucleotide Cohort 2 Representative Histology Cohort 2 biopsy at Week 24 sh

  15. Slide 15: Neuromuscular Function: CHOP INTEND and Developmental Milestones

    Neuromuscular Function CHOP INTEND and Developmental Milestones

  16. Slide 16: Significant Improvements in Neuromuscular Function

    64 Control patients Patient ID Baseline score Latest score Change from baseline (%) Cohort 1 1 29 56 (Wk48) +93 2 45 64 (Wk48) +42 3 34 39 (Wk48) +15 4 49 47 (Wk48) -4 5 36 63 (Wk48) +75 6 39 53 (Wk48) +36 7 43 64 (Wk48) +49 Cohort 2 8 36 61 (Wk24) +69 9 39 55 (Wk24) +41 10 29 46 (Wk24) +59 11 42 37

  17. Slide 17: Mean Increase in CHOP INTEND Score

    CHOP INTEND, Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders BL, baseline; LS, Least Squares Bars indicate standard error Interim data as of April 8, 2019 LS Mean Increase in CHOP INTEND Score Treated patients showed sustained clinical improvements in motor function Treate

  18. Slide 18: Motor Milestones: Head Control

    Motor Milestones: Head Control Treated patients show progressive attainment of milestones regardless of age Months after birth Age 1 Age 2 Age 3 Age 4 Age 5 Age 6 Age 7 1 2 3 4 5 6 7 8 9 10 11 12 Head control 1 11 2 9 5 10 4 6 7 8 Interim data as of April 8, 2019 Patient 3 not evaluable because of h

  19. Slide 19: Motor Milestones: Rolling From Back to Stomach

    Motor Milestones: Rolling From Back to Stomach Treated patients show progressive attainment of milestones regardless of age Months after birth Age 1 Age 2 Age 3 Age 4 Age 5 Age 6 Age 7 1 2 3 4 5 6 7 8 9 10 11 12 Rolling from back to stomach 1 11 2 9 5 10 4 6 7 8 Interim data as of April 8, 2019 Pati

  20. Slide 20: Motor Milestones: Sitting 30 sec Without Support

    Motor Milestones: Sitting 30 sec Without Support Treated patients show progressive attainment of milestones regardless of age Months after birth Age 1 Age 2 Age 3 Age 4 Age 5 Age 6 Age 7 1 2 3 4 5 6 7 8 9 10 11 12 Sitting 30 sec without support 1 11 2 9 5 10 4 6 7 8 Interim data as of April 8, 2019

  21. Slide 21: Motor Milestones: Makes Stepping Movements

    Motor Milestones: Makes Stepping Movements Treated patients show progressive attainment of milestones regardless of age Months after birth Age 1 Age 2 Age 3 Age 4 Age 5 Age 6 Age 7 1 2 3 4 5 6 7 8 9 10 11 12 Makes stepping movements 1 11 2 9 5 10 4 6 7 8 Interim data as of April 8, 2019 Patient 3 no

  22. Slide 22: Respiratory Function: MIP and Ventilator Dependence

    Respiratory Function Maximal Inspiratory Pressure (MIP) and Ventilator Dependence

  23. Slide 23: Significant Improvements in Respiratory Function

    MIP 80 cmH2O: Estimated lower limit of normal in healthy children <5 years of age MIP (cmH2O) Weeks after ASPIRO baseline BL Uncuffed tracheostomy, gas leak: Patients 7 and 8 Significant Improvements in Respiratory Function Interim data as of April 8, 2019 MIP, maximum inspiratory pressure BL, basel

  24. Slide 24: Sustained Clinically Meaningful Improvement in Respiratory Strength

    MIP, maximal inspiratory pressure; ctrl, control; BL, baseline; Wk, week LS, Least Squares means estimated with Repeated Measures ANOVA Model Bars indicate standard error Interim data as April 8, 2019 Sustained Clinically Meaningful Improvement in Respiratory Strength in Treated Patients Weeks after

  25. Slide 25: Significant and Rapid Reductions in Ventilator Use in All Treated Patients

    Significant and Rapid Reductions in Ventilator Use in All Treated Patients Interim data as of April 8, 2019 Cohort 1: 1x1014vg/kg; Cohort 2: 3x1014vg/kg BiPAP, bilevel positive airway pressure; BL, baseline; Inv, invasive; Wk, week Ventilator independence achieved by 4 patients to date Interim data

  26. Slide 26: Reductions in Ventilator Dependence Not Previously Observed in NMD

    NMD, neuromuscular disease; BL, baseline; LS, Least Squares means estimated with Repeated Measures ANOVA Model Bars indicate standard error Interim data as April 8, 2019 Treated Patients Have Achieved Reductions in Ventilator Dependence Not Previously Observed in Chronically Ventilated Patients with

  27. Slide 27: Patient Video

    Patient Video Please: No photographic or video recordings of patient videos

  28. Slide 28: Key Findings to Date of ASPIRO

    Interim data as of April 8, 2019 ASPIRO Key Findings to Date AT132 has been generally well tolerated and has shown manageable safety profile across both dose cohorts Muscle biopsies show robust dose-dependent transduction, transcription, protein expression and histological improvements through Week

  29. Slide 29: Acknowledgements

    Acknowledgements XLMTM Preclinical Studies and ASPIRO Clinical Trial Anna Buj Bello Genethon Martin K. (Casey) Childers David Mack University of Washington, USA Alan H. Beggs Children’s Hospital Boston, USA Michael W. Lawlor Children’s Hospital and Medical College of Wisconsin, USA My team at the UC

Audentes Therapeutics — Technical Presentation (May 2019) on 6ix